Funding opportunity from the Office of Research. Bridge Fund Award applications will be accepted until 12/1/25. Go HERE for more information.

Artificial Intelligence and Technology Collaboratory Coordinating Center (U24 Clinical Trial Not Allowed)

2 months 2 weeks ago
Funding Opportunity RFA-AG-26-007 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) invites Cooperative Agreement (U24) applications for the National Institute on Aging (NIA) Artificial Intelligence and Technology Collaboratory (AITC) Coordinating Center (AITCC). The AITC Program promotes the development and implementation of artificial intelligence approaches and technology through research projects for aging and AD/ADRD research. The central functions of the AITCC are to (1) serve as a hub for the AITC Program and facilitate and coordinate activities across the AITC Program, (2) centralize and lead key stakeholder engagement activities across the AITC Program, and (3) enhance the scientific impact and reach of the AITC Program by actively disseminating information about the program and attracting new researchers from across the country to participate in program activities and resources.

Artificial Intelligence and Technology Collaboratory (P30 Clinical Trial Optional)

2 months 2 weeks ago
Funding Opportunity RFA-AG-26-006 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) invites Center Core (P30) applications for the National Institute on Aging (NIA) Artificial Intelligence and Technology Collaboratories (AITC) program. The AITC Program promotes the development and implementation of artificial intelligence approaches and technology through research projects for aging and AD/ADRD research. All applications should propose strategies for addressing ethical challenges surrounding artificial intelligence and technologydevelopment and implementation, and to employ, when possible, best practices established in the fields of aging and AD/ADRD.

Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)

2 months 2 weeks ago
Funding Opportunity PAR-25-446 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity (NOFO) is to solicit grant applications to support research on the discovery and development of interventions to prevent and/or treat substance use disorders (SUDs) and overdose, including medications and medical devices to treat co-morbid SUDs. This includes preclinical and clinical research studies that will have high impact and quickly yield the necessary results to advance candidate interventions closer to regulatory approval or clinical adoption. This NOFO will utilize the UG3/UH3 activity code.

Claude D. Pepper Older Americans Independence Centers (P30 Clinical Trial Optional)

2 months 2 weeks ago
Funding Opportunity RFA-AG-26-025 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) invitesapplications for the Claude D. Pepper Older Americans Independence Centers (OAICs) award. The goal of the OAIC program is to establishcenters of excellence in geriatrics research and research education to increase scientific knowledge leading to better ways to maintain or restore independence in older persons. OAIC awards are designed to develop or strengthen programs that focus on, and sustain progress in, a key area of aging research related to the mission of the OAIC program.

Nonhuman Primate Reagent Resource (U24 Clinical Trial Not Allowed)

2 months 3 weeks ago
Funding Opportunity RFA-AI-25-010 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to continue support for a nonhuman primate (NHP) reagent resource that enables rigorous and reproducible research in NHP models through the development, production, and distribution of NHP-specific immunologic reagents that are not commercially available or, if commercially available, are not optimized for use in NHPs. The over-arching goal is to accelerate cures, vaccines, and treatments for immune-mediated diseases and emerging and reemerging infectious diseases by facilitating robust preclinical research in NHPs.